Edition:
United Kingdom

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

14.79USD
16 Oct 2018
Change (% chg)

$0.91 (+6.56%)
Prev Close
$13.88
Open
$14.07
Day's High
$14.86
Day's Low
$13.92
Volume
530,689
Avg. Vol
482,444
52-wk High
$27.50
52-wk Low
$11.35

Latest Key Developments (Source: Significant Developments)

Sangamo Therapeutics Q2 Loss Per Share $0.17
Wednesday, 8 Aug 2018 

Sangamo Therapeutics Inc ::SANGAMO THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $21.4 MILLION VERSUS I/B/E/S VIEW $21.4 MILLION.Q2 LOSS PER SHARE $0.17.Q2 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.SEES DECEMBER 31, 2018 BALANCE OF CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND INTEREST RECEIVABLE OF AT LEAST $380 MILLION.  Full Article

TxCell Says Sangamo Therapeutics Files Tender Offer On Its Shares
Monday, 23 Jul 2018 

July 23 (Reuters) - TXCELL SA ::SANGAMO THERAPEUTICS TO ACQUIRE TXCELL.PRICE OF EUR 2.58 PER SHARE IN CASH.APPROXIMATELY EUR 72 MILLION, ON A DEBT-FREE AND CASH-FREE BASIS.SUBJECT TO SATISFACTION OF CLOSING CONDITIONS, SANGAMO EXPECTS TO COMPLETE TRANSACTION IN FOURTH QUARTER OF 2018.SANGAMO EXPECTS TO COMPLETE TRANSACTION IN Q4 OF 2018.  Full Article

Sangamo Therapeutics To Acquire TxCell
Monday, 23 Jul 2018 

July 23 (Reuters) - SANGAMO THERAPEUTICS INC ::SANGAMO THERAPEUTICS TO ACQUIRE TXCELL.SANGAMO EXPECTS THAT PROPOSED ACQUISITION OF TXCELL WOULD ACCELERATE COMPANY'S ENTRY INTO CLINIC WITH A CAR-TREG THERAPY.SANGAMO EXPECTS TO COMPLETE TRANSACTION IN Q4 OF 2018.  Full Article

Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.23
Tuesday, 8 May 2018 

May 8 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $12.6 MILLION VERSUS $3.4 MILLION.Q1 REVENUE VIEW $53.1 MILLION -- THOMSON REUTERS I/B/E/S.Q1 LOSS PER SHARE $0.23.Q1 EARNINGS PER SHARE VIEW $0.48 -- THOMSON REUTERS I/B/E/S.SAYS EXPECTS THAT OPERATING EXPENSES WILL BE IN RANGE OF $140 MILLION TO $150 MILLION FOR YEAR-END 2018.  Full Article

Sangamo Therapeutics Prices Public Offering Of Common Stock
Thursday, 26 Apr 2018 

April 25 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 12.3 MILLION COMMON SHARES PRICED AT $16.25PER SHARE.  Full Article

Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Pfizer Inc ::SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS​ - CO, ‍PFIZER ANNOUNCED COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS INC - UNDER TERMS OF COLLABORATION AGREEMENT, SANGAMO WILL RECEIVE A $12 MILLION UPFRONT PAYMENT FROM PFIZER.SANGAMO THERAPEUTICS INC - UNDER AGREEMENT, CO ‍WILL BE RESPONSIBLE FOR DEVELOPMENT OF ZFP-TF CANDIDATES​.SANGAMO - UNDER TERMS ELIGIBLE TO RECEIVE POTENTIAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS UP TO $150 MILLION, TIERED ROYALTIES ON NET SALES.SANGAMO - UNDER DEAL,‍PFIZER OPERATIONALLY,FINANCIALLY RESPONSIBLE FOR RESEARCH,DEVELOPMENT,COMMERCIALIZATION FOR C9ORF72 ZFP-TF,RESULTING PRODUCTS.  Full Article

Sangamo Says European Medicines Agency Recommends Orphan Medicinal Product Designation For Investigational Genome Editing Treatments
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO ANNOUNCES EUROPEAN MEDICINES AGENCY RECOMMENDATION OF ORPHAN MEDICINAL PRODUCT DESIGNATION FOR INVESTIGATIONAL GENOME EDITING TREATMENTS FOR MPS I AND MPS II.SANGAMO THERAPEUTICS - PHASE 1/2 CLINICAL TRIALS FOR PROGRAMS, EVALUATING SB-318 & SB-913 IN ADULTS WITH MPS I AND MPS II, ARE ENROLLING SUBJECTS.  Full Article

Sangamo says patient received therapy intended to precisely edit DNA of cells directly inside body​
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Sangamo Therapeutics Inc -:Sangamo announces treatment of first patient in landmark phase 1/2 clinical trial evaluating in vivo genome editing for MPS II.‍A patient has received a therapy intended to precisely edit DNA of cells directly inside body​.  Full Article

Sangamo Therapeutics posts Q3 loss per share $0.15
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sangamo Therapeutics Inc :Sangamo Therapeutics reports third quarter 2017 financial results.Q3 revenue $11.8 million versus I/B/E/S view $10.4 million.Q3 loss per share $0.15.Sees FY 2017 revenue $30 million to $40 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Sangamo Therapeutics Inc - ‍company expects that revenues will be in range of $30 million to $40 million in 2017​.FY2017 revenue view $33.2 million -- Thomson Reuters I/B/E/S.  Full Article

UPDATE 3-U.S. FDA expands approval of Roche hemophilia drug

Oct 4 Roche on Thursday said U.S. regulators approved expanded use of its drug Hemlibra to include almost all patients with hemophilia A, as the Swiss drugmaker increases its focus on diseases beyond cancer to help replace revenue from older products that have lost patent protection.